During the quarter, profit before tax (PBT) stood at Rs 122.86 crore, declining 16.54% quarter-on-quarter but rising 148.4% year-on-year.

EBITDA stood at 121.0 crore in Q1 FY26, down 13.57% QoQ and up 173.14% YoY. EBITDA margin was at 34.1% in Q1 FY26 as against 27.2% in Q1 FY25.

Shiven Arora, managing director, Blue Jet Healthcare, said, “Blue Jet Healthcare clocked a revenue of Rs 354.8 core, a growth of 117.8% YoY with EBITDA coming in at Rs 121.0 crore. This was primarily driven by the ramp up in PI & API product categories. The robust growth, coupled with strong EBITDA margins, reflects our focus on operational efficiency and a solid business foundation.

Looking ahead, we remain confident in our growth strategy, driven by capacity expansions, enhanced R&D capabilities, and a robust pipeline of high-value products. We are committed to delivering long-term value to our stakeholders through consistent performance, innovation, and strategic investments.”

Blue Jet Healthcare is a specialty pharmaceutical and healthcare ingredient and intermediate company, operating under a contract development and manufacturing organization (CDMO) business model. The company has specialized chemistry capabilities in contrast media intermediates and high-intensity sweeteners.